1 Structural analogues of a sulphated polysaccharide, dextrin sulphate, were synthesized and tested for their ability to block infection by HIV-1. Using the T-cell lines, C8166 and HPB-ALL, and the laboratory adapted strains of HIV-1.MN, HIV-l.IIIb and HIV-1.RF, dextrin 2-sulphate (D2S) combined the best combination of high anti-HIV-1 activity (95% inhibitory concentration (IC95) 
Introduction
Infection by the Human Immunodeficiency Virus-I (HIV-1) is a prerequisite for the development of the Acquired Immune Deficiency Syndrome (AIDS) which is characterized by a progressive loss of CD4 positive T-cells. Infection of these cells is initiated by the binding of the viral envelope glycoprotein gpl2O to the cell surface protein CD4, following which there is a temperature-dependent dissociation of gpl20 from the viral envelope (Dalgleish et al., 1984; Klatzmann et al., 1984; Maddon et al., 1986; Hart et al., 1991; Dimitrov et al., 1992; Klasse & Moore, 1992) . This exposes gp4l which is believed to be involved in the fusion of the virion with the cell membrane (Brasseur et al., 1988) . The mechanism of viral entry however remains obscure.
Endogenous sulphated polysaccharides have a role in cell adhesion and cell recognition (Rossignol et al., 1984; Yamaguchi et al., 1985; Cole et al., 1986; Coombe et al., 1987) and have been implicated in the binding of lymphocytes to endothelial venules (Stoolman & Rosen, 1983; Brenan & Parish, 1986; Coombe & Rider, 1989) . More recently, sulphated polysaccharides have become the focus of renewed interest because they block infection of T-cell lines by laboratory adapted strains of HIV-1 in vitro. A variety of Author for correspondence. compounds have been studied; fucoidan, dextran sulphate, pentosan polysulphate, mannan sulphate, lentinan sulphate, sulphated bacterial glycosaminoglycan, dextrin 2-sulphate, heparin and fragmented derivatives of heparin (Ito et al., 1987; Ueno & Kuno, 1987; Baba et al., 1988b; Bagasra & Lischner, 1988; McClure et al., 1991; Beddows et al., 1993) . In previous studies, D2S was shown to block infection of human T-cell lines by a variety of laboratory adapted cell-free isolates of HIV-1 (McClure et al., 1991; Beddows et al., 1993) .
It remains to be established whether the large family of sulphated polysaccharides which block HIV-1 infection share a common mechanism of action or whether several different mechanisms are responsible for their anti-HIV-1 activity. In the case of D2S, fucoidan and dextran sulphate, previous studies have suggested that they block HIV-1 infection by acting at the level of the cell surface but they did not characterize this binding (Mitsuya et al., 1988; Baba et al., 1988a; McClure et al., 1991; Beddows et al., 1993) . The identification and characterization of a cell surface receptor to which D2S binds and blocks HIV-1 infection has important implications for therapy. In this paper, we have synthesized structural variants of dextrin sulphate and used them to study the binding of these compounds to T-cells.
Methods

Synthesis of D2S and its analogues
Limit dextrin (ML Labs, Waverley, Liverpool) was produced by enzymatic hydrolysis of starch and purified by ultra filtration and passage through absorptive filters. The product complies with the British Pharmacopoeia monograph for dextrin and consists predominantly of a-1, 4 linked glucan units. D2S was synthesized by sulphation of a solution of dextrin (40 g in 40 ml water) at room temperature using sulphur trioxide-trimethylamine complex (60 g) in the presence of sodium hydroxide (16.8 g). The stirred mixture was maintained alkaline over 12 h with 5 M sodium hydroxide. Excess reagent was removed by dialysis against water and the product recovered after freeze-drying. Dextrin 2,3,6-trisulphate was prepared in the same way as D2S but with a large excess of the sulphating agent.
Dextrin 3-sulphate was prepared from dextrin (16.2 g) after being acetylated over 2 d with acetic anhydride (20.4 g) and triethylamine (10 g) in dimethylformamide (150 ml). The product (12.3 g), predominantly the 2,6-diacetyl derivative, was collected by precipitation after the addition of water, dissolved in dimethylformamide (75 ml) and sulphated with trimethylamine-sulphur trioxide complex (25 g) over 24 h. The mixture was poured into acetone (500 ml) to yield a sticky residue and the supernatant decanted. The residue was dissolved in water (150 ml) and saponified with sodium hydroxide (5 g) to remove the acetyl groups. The dextrin 3-sulphate mixture was finally dialysed against water and freeze-dried.
Dextrin 6-sulphate was prepared by sulphation of dextrin (10 g) in dimethylformamide (100 ml) with cyclamic acid (22.5 g) at 78C over 1.5 h. The mixture was made alkaline with sodium hydroxide in aqueous ethanol (10%; 50 ml) and then poured into diethyl ether (400 ml). The resultant solid was washed with ether, dissolved in sodium acetate solution (50%; 100 ml), dialysed against water and freeze-dried.
Dextrin 2-(2-hydroxypropyl-3-trimethylammonium salt) was prepared by stirring dextrin (81 g) in 5% sodium hydroxide (240 ml) with glycidyltrimethylammonium chloride (120 g) for 12 h at 20C. The resulting solution was dialysed against water and freeze-dried. Dextrin 2-(2-hydroxypropyl-3-triethylammonium salt) was prepared in the same way except that glycidyltriethylammonium chloride was used in place of glycidyltrimethylammonium chloride.
Dextrin and its sulphated derivatives were characterized by sulphate analysis, Fourier transformed infra red spectra recorded in KBr discs and '3C n.m.r.
Synthesis of radiolabelled D2S
[3H]-D2S was prepared by partial alkylation of D2S with [3H]-methyl iodide in dimethylformamide in the presence of a silver (I) oxide catalyst. A stirred solution of D2S (27.7 mg) and silver (I) oxide (10 mg) in dimethylformamide (2 ml) was treated dropwise with [3H]-methyl iodide (3.74 mg in 1 ml of toluene; specific activity 80 Ci mmol-', Amersham, Bucks) over 4 h at room temperature. Distilled water (5 ml) was then added with vigorous stirring before the mixture was allowed to separate into aqueous and organic layers. The organic layer was removed. The residual aqueous phase was dialysed against distilled water (8 x 101) followed by gel filtration to yield D2S in which it was estimated that in 500-1000 glucan units was [3H]-methylated (specific activity 70-200 mCi mmol-'). This degree of methylation did not affect its anti-HIV-I activity.
Cell lines and primary cells
The human T-cell lines studied were HPB-ALL (Morikawa et al., 1978) , CEM (Foley et al., 1965) , C8166 (Salahuddin et al., 1983) and H9 (Popovic et al., 1984) . The human epithelial-like cell line HeLa (Scherer et al., 1953) and the HeLa cell line transfected with the gene for human CD4 (Chesebro & Wehrly, 1988) Freshly isolated PBMN cells were also incubated with
LGM containing 1.0 fig ml-' of the monoclonal antibody OKT3 (anti-CD3, a T-cell specific activator antibody) (Roosnek et al., 1990) or with LGM containing 20 iu recombinant IL-2 ml-' and one of several cytokines (Schrier et al., 1993) (1 ngml-' human recombinant IL-1a, 1 ngml-'
human recombinant IL-1P, 50 ng ml-' human recombinant IL-4 and 50 ng ml-' human recombinant IL-6; Genzyme Diagnostics, Kent) for up to 72 h prior to being washed with PBS/2% (v/v) FCS and binding studies being performed.
Infectivity assays
The HIV-1 isolates HIV-1.MN, HIV-l.IIIb and HIV-1.RF were obtained through the MRC AIDS Directed Programme and were propagated in H9 cells. Cell free supernatants containing HIV-1 were prepared by lysis of acutely infected H9 cells and centrifugation of the cellular debris at 400 g for 5 min. The titre of virus was determined by endpoint dilution of the viral supernatant on C8166 cells (Lifson et al., 1986; McClure et al., 1991) . Productive infection resulted in the formation of syncytia in the C8166 cells and the result was recorded as the tissue culture infectious dose (TCID). Syncytial assays and/or measurement of the major core protein of HIV-1 (p24) were used to determine the anti-HIV-1 activity of D2S and its analogues. Cells were incubated with the test compound for 1 h at 37°C prior to the addition of HIV-1. The cultures were then assessed by light microscopy on a daily basis for 5 days for the formation of syncytia and/or cell free culture supernatants collected for measurement of p24 (EIA, Coulter, Luton, Beds). The ability of D2S to block infection of PBMN cells by primary viral isolates of HIV-1 was also determined. These isolates were grown from HIV-1 positive patients by culturing their PBMN cells (2 x 106 ml-') with an equal number of PHA activated PBMN cells from seronegative donors (Hollinger et al., 1992) . The co-culture was fed every 4 days with fresh LGM containing IL-2 and fresh PHA activated PBMN cells (0.5 x 106 cells ml-'). Cell free supernatants were collected 10 days after the start of the co-culture and stored in liquid nitrogen until use. The titre of the primary viral isolate was determined by endpoint dilution of the viral supernatant on PHA stimulated PBMN cells. Productive infection was determined by measurement of p24 in cell free culture supernatants and the result recorded as the TCID.
The anti-HIV-1 activity of the compounds studied was determined using PHA stimulated PBMN cells which, after washing, had been resuspended in fresh LGM containing IL-2 (20 iu ml-'). They were then incubated with D2S (20-100 ILg ml') for 1 h at 370C. Following this, either HIV-1.MN (101 TCID) or one of 5 primary viral isolates of HIV-1 (10'-102 TCID) was added to the culture. After 24 h, the cells were washed with PBS/2% (v/v) FCS and cultured in LGM containing IL-2 (20 iu ml-') for a further 4 days. Cell free culture supernatants were then collected, filtered and p24 measured. The inhibitory concentration (IC95) of each compound was defined as the concentration which reduced the level of p24 in cell free supernatants by 95% as compared to the positive control. The IC95 was measured in preference to the IC50 because studies with recombinant soluble CD4 have suggested that its inhibitory effect on plasma viraemia correlates with the in vitro IC95 of the viral isolate and not its IC50 (Schacker et al., 1994) .
Anticoagulant assays
Thrombin mediated fibrin formation was measured in pooled human plasma. Compounds were diluted in plasma/veronal buffer (2/1, pH 7.35) and incubated at 37TC for 30 min. Receptor-ligand binding studies C8166 cells were used to determine the anti-HIV-1 activity of the compounds synthesized. However, although they are an ideal T-cell line for infection screening assays, they were not used for the binding assays because they grow in clumps which are difficult to separate into individual cells. HPB 
Results
Synthesis of modified dextrins
Since dextrin is a polymer comprising repeat units, chemical modification such as sulphation yields a product which is predominantly (but not exclusively) modified at the same site of each repeating unit. Elemental and spectroscopic analysis provide evidence for, and distinguished between, the various sites of modification. The mol. wt. of D2S was calculated as 27 kDa on the basis of the incorporation of 1 sulphate per glucan unit (see below).
The sulphate content of the dextrin 2-, 3-, and 6-sulphates was determined by elemental analysis as 37%, being equivalent to one sulphate per glucan moiety. In the case of dextrin 2,3,6-trisulphate, the sulphate content was determined as 70%, this being equivalent to complete hydroxyl substitution (three sulphate groups per glucan).
Sulphated dextrins all yielded infrared specta with a band at about 1220 cm-' characteristic of the presence of sulphate and another band between 820 cm-' and 840 cm-'. Neither of these bands were present in the infrared spectrum of dextrin itself. A peak at 820 cm-' has been reported as typical for primary sulphates of sugars, i.e. for 6-substitution, whereas equatorial secondary sulphate gives a peak at 835 cm-' (Turvey, 1965) .
By comparison to authentic reference sugars, the 13C n.m.r. spectrum of dextrin was assigned as follows; the C-1 acetal carbon is to lowest field, 100.3 p.p.m. and the primary C-6 is to the highest field near 61 p.p.m. Between these two are C-4 (77.6 p.p.m.), C-3 (73.9 p.p.m.), C-2 (72.2 p.p.m.) and C-5 (71.8 p.p.m.). 69.3 p.p.m. A similar upfield shift of 1.7 p.p.m. has been reported for the 6-0-sulphation of glucose (Bock & Pedersen, 1983 ).
In the '3C n.m.r. spectrum of dextrin 2-(2-hydroxypropyl- 
Infectivity and anticoagulent measurement
The anti-HIV-1 activity (as determined in C8166 cells and 3 laboratory adapted strains of HIV-1) and the anticoagulant activity of dextrin sulphate were affected by the number and position of the sulphate groups present. D2S, dextrin 6-sulphate and dextrin 2,3,6-trisulphate were potent anti-HIV-1 compounds with similar IC95 values (Table 1 ). Amongst the compounds tested, D2S had the shortest thrombin time and dextrin 2,3,6-trisulphate the longest (Table 1) . The 3-sulphated derivative had poor anti-HIV-1 activity (Table 1 ) although its thrombin time was similar to that for dextrin 6-sulphate (D6S) ( Table 1) . Dextrin 2-(2-hydroxypropyl-3-trimethylammonium salt) and dextrin 2-(2-hydroxypropyl-3-triethylammonium salt) had no anti-HIV-l activity ( infection by HIV-1 following activation is not due to an increased cell surface expression of CD4 (Gowda et al., 1989) . Dextrin 2-sulphate was found to block infection of PHA activated PBMN cells by 5 primary viral isolates with an IC9, of 230-3700 nM depending upon the primary viral isolate tested as determined by the measurement of p24 in cell free culture supernatants.
Receptor-ligand binding studies
Competition binding studies In competition binding studies using HPB-ALL cells, dextrin 6-sulphate, dextrin 3-sulphate and dextrin 2,3,6-trisulphate were all effective inhibitors of [3H]-D2S binding (Table 1; Figure 1 ). The positively charged molecules, dextrin 2-(2-hydroxypropyl-3-trimethylamine) and dextrin 2-(2-hydroxypropyl-3-triethylamine), did not inhibit [3H]-D2S binding and had no anti-HIV-l activity. Similarly, dextrin, glucose 6-phosphate and sodium sulphate had no anti-HIV-1 activity and did not displace [3H]-D2S (Table 1) .
Competition binding studies were also performed using several naturally occurring sulphated polysaccharides and polyanionic compounds which have anti-HIV-l activity. Of those tested, fucoidan was the most effective competitor (Table 1) . Dextran sulphate (8 kDa) was less effective than the sulphated derivatives of dextrin. Pentosan polysulphate did not compete at all whilst auran tricarboxylic acid competed very poorly.
Saturation binding studies on T-cell lines [3H]-D2S bound to
HPB-ALL cells in a specific and saturable manner (Figure 2 The inhibitory concentration (IC95) is the mean concentration of the compound which blocked infection by HIV-1.MN, HIV-1l.IIb and HIV-1.1.RF of C8166 cells by 95% as measured by syncytia formation and HIV-1 p24. The thrombin time was measured using the concentration of each compound which corresponded to the IC95 for its anti-HIV-1 activity. Competition binding studies were performed with HPB-ALL cells. The inhibitory constant (Ki) was determined from these experiments using the concentration of the competing compound which inhibited the binding of [3H]-D2S by 50%.
Results are shown as the mean ± s.e.mean. ND = not done. Infection of these cells is blocked by D2S (McClure et al., 1991; Shaunak, 1993 Fucoidan is thought to share a similar mechanism of action to D2S for its anti-HIV-1 activity (McClure et al., 1992) in contrast to pentosan polysulphate which binds to CD4 (Parish et al., 1990) . Aurin tricarboxylic acid, which also blocks HIV-1 infection by binding to CD4 (Schols et al., 1989; Szabo et al., 1992) formation in C8166 cells and HIV-1 p24 levels. We have also shown that HIV-1 proviral DNA cannot be detected by PCR in cells incubated with D2S and then exposed to HIV-1 (Bieniasz et al., 1991; Shaunak, 1993) , providing evidence that D2S prevents HIV-1 infection by blocking viral entry into cells. In view of the recent observation that the concentration of recombinant soluble CD4 which blocks infection of PBMN cells by primary viral isolates of HIV-1 is 200-2700 times greater than that required to block infection of T-cell lines by laboratory adapted isolates of HIV-1 (Daar et al., 1990) , the activity of D2S against primary viral isolates of HIV-l was also tested. D2S blocked infection of PHA activated PBMN cells by several different primary viral isolates at concentrations that were up to 16 times higher than those required to block laboratory adapted isolates. D2S therefore has potential as a clinically useful compound.
All the T-cell lines examined bound [3H]-D2S and the addition of PHA or IL-2 to the culture media did not alter the Bmax of binding (data not shown). In contrast, the binding of [3H]-D2S to freshly isolated PBMN cells increased when the cells were cultured in LGM with PHA to a Bmax that was almost double that for the T-cell lines that we studied ( 
